Results 81 to 90 of about 3,635,661 (309)

The reporting of health systems data use in primary results publications of clinical trials: a systematic review

open access: yesTrials
Background Data collected within clinical trials often overlaps with routinely collected Health Systems Data (HSD). There is potential for HSD to reduce burdens for trials and understanding HSD use can help triallists make decisions about using HSD in ...
Jemima Thompson   +5 more
doaj   +1 more source

Cisplatin-based chemotherapy of testicular cancer - Two decades after a major breakthrough [PDF]

open access: yes, 2000
Two decades ago the introduction of cisplatin-based combination chemotherapy has dramatically improved the prognosis of patients with metastatic testicular cancer, At present 3 cycles of cisplatin, etoposide and bleomycin are considered as standard ...
Gerl, Arthur
core   +1 more source

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

open access: yesMolecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti   +10 more
wiley   +1 more source

Cluster randomised controlled feasibility study of HENRY: a community-based intervention aimed at reducing obesity rates in preschool children

open access: yesPilot and Feasibility Studies, 2018
Background In the UK and beyond, public funding is used to commission interventions delivered in public health early years settings aimed at improving health and well-being and reducing inequalities in order to promote school readiness.
Maria Bryant   +7 more
doaj   +1 more source

Multi-center clinical trials: Randomization and ancillary statistics

open access: yes, 2008
The purpose of this paper is to investigate and develop methods for analysis of multi-center randomized clinical trials which only rely on the randomization process as a basis of inference.
Zelen, Marvin, Zheng, Lu
core   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

open access: yesMolecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani   +14 more
wiley   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

open access: yesMolecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez   +17 more
wiley   +1 more source

Monitoring in practice – How are UK academic clinical trials monitored? A survey

open access: yesTrials, 2020
Background Despite the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) encouraging the use of risk-based monitoring for trials in 2013, there remains a lack of evidence-based guidelines on how to monitor.
Sharon B. Love   +3 more
doaj   +1 more source

Climbing as an Add-On Treatment Option for Patients with Severe Anxiety Disorders and PTSD: Feasibility Analysis and First Results of a Randomized Controlled Longitudinal Clinical Pilot Trial [PDF]

open access: gold, 2022
Carina S. Bichler   +8 more
openalex   +1 more source

Home - About - Disclaimer - Privacy